New study tracks targeted drug zanubrutinib in rare blood cancer
NCT ID NCT05640102
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 37 times
Summary
This study is tracking how well the drug zanubrutinib works and its safety in people with Waldenström macroglobulinemia, a rare blood cancer. Researchers are especially interested in patients with specific genetic mutations and those from racial and ethnic minority groups. The study will collect information from medical records and follow participants over time to see how they respond to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010-3012, United States
-
Clearview Cancer Institute
RECRUITINGHuntsville, Alabama, 35805-2606, United States
-
Comprehensive Cancer Centers of Nevada
RECRUITINGLas Vegas, Nevada, 89169-3321, United States
-
Eisenhower Medical Center, Lucy Curci Cancer Center
RECRUITINGRancho Mirage, California, 92270-3221, United States
-
Hattiesburg Hematology and Oncology Clinic
RECRUITINGHattiesburg, Mississippi, 39401-7233, United States
-
Los Angeles Cancer Network (Lacn)
RECRUITINGGlendale, California, 91204-3640, United States
-
Pan American Oncology Trials, Llc
RECRUITINGRio Piedras, 00935, Puerto Rico
-
South Alabama Medical Science Foundation Mitchell Cancer Institute
RECRUITINGMobile, Alabama, 36604-1405, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (a targeted cancer drug, also called Brukinsa)
What this could lead to
If successful, this study could confirm that zanubrutinib is effective and safe for a broader range of patients with Waldenström macroglobulinemia, including those from racial and ethnic minority groups.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also relatively small (111 participants) and focuses on a rare blood cancer, so findings may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.